UPDATED May 03, 2024
Companies which may present a buying opportunity after a dip in share price.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ACI | ₹657.70 | -1.4% | 19.8% | ₹81.2b | ₹743.00 | PE20.4x | E29.0% | 0.3% | Materials | ||
CAI | AU$0.13 | -3.8% | -35.9% | AU$95.2m | n/a | PB0.7x | E110.6% | n/a | Materials | ||
A036200 | ₩10,770.00 | -3.0% | 45.1% | ₩321.9b | ₩13,500.00 | PE17.7x | E38.6% | 0.7% | Semiconductors | ||
HHR | AU$0.007 | 0% | -75.9% | AU$19.7m | n/a | PE6.7x | E86.3% | n/a | Energy | ||
ZVRA | US$4.81 | 6.4% | -2.0% | US$198.8m | US$19.00 | PS7.3x | E63.6% | n/a | Pharmaceuticals & Biotech | ||
NEWBRY | kr3.23 | -5.3% | -42.7% | kr78.4m | kr8.00 | PS3.4x | E112.9% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$8.75 | 2.7% | -46.5% | US$225.0m | US$25.90 | PS4.5x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
301358 | CN¥35.02 | 8.7% | -11.9% | CN¥26.5b | n/a | PE18.2x | E30.3% | 1.2% | Capital Goods | ||
301325 | CN¥61.62 | -2.8% | n/a | CN¥7.4b | CN¥83.82 | PE22.3x | E24.9% | n/a | Capital Goods | ||
A101390 | ₩8,140.00 | -7.6% | -18.1% | ₩73.4b | n/a | PB3.2x | E100.8% | n/a | Tech | ||
KCB | KSh29.50 | -2.2% | -6.6% | KSh94.8b | KSh51.24 | PB0.4x | E26.0% | 0% | Banks | ||
SONM | US$0.54 | 10.7% | -43.1% | US$23.5m | US$2.00 | PB1x | E139.9% | n/a | Tech | ||
CLBIO | kr10.45 | 1.5% | -24.0% | kr224.6m | kr29.00 | PS6.3x | E102.9% | n/a | Pharmaceuticals & Biotech | ||
DIGN | kr1.60 | 3.9% | -62.5% | kr112.8m | kr8.60 | PS1.3x | E139.0% | n/a | Healthcare | ||
SEAPT | kr4.62 | 1.3% | -63.4% | kr1.7b | kr11.57 | PB0.9x | E54.2% | n/a | Energy | ||
FTCI | US$0.54 | 26.6% | -79.2% | US$58.7m | n/a | PB1.1x | E63.1% | n/a | Capital Goods | ||
FXPO | UK£0.50 | -2.3% | -54.2% | UK£295.9m | UK£1.41 | PB0.3x | E116.3% | 0% | Materials | ||
4071 | ر.س217.00 | 1.0% | 71.1% | ر.س10.9b | ر.س275.17 | PE33.9x | E27.1% | 1.1% | Media | ||
300442 | CN¥31.41 | 1.7% | -1.8% | CN¥54.0b | CN¥36.36 | PE28.3x | E28.7% | 1.6% | Software | ||
ACR | AU$0.065 | 8.3% | 23.8% | AU$18.9m | n/a | PS1.7x | E115.3% | 0% | Pharmaceuticals & Biotech | ||
CABP | UK£1.40 | 2.8% | n/a | UK£355.8m | UK£1.78 | PE15.6x | E34.6% | n/a | Diversified Financials | ||
OX2 | kr39.70 | -2.2% | -45.4% | kr10.8b | kr70.75 | PE12.3x | E29.9% | n/a | Capital Goods | ||
FLNC | US$20.90 | 24.0% | 16.6% | US$3.5b | US$30.38 | PS1.2x | E65.2% | n/a | Capital Goods | ||
XBRANE | kr0.20 | -5.4% | -99.8% | kr309.0m | n/a | PS1.3x | E93.7% | n/a | Pharmaceuticals & Biotech |